A族链球菌疫苗研究进展  

Research progress in group A streptococcus vaccines

作　　者：王翔 黄文华 姜永强 赵国芬[1] WANG Xiang;HUANG Wenhua;JIANG Yongqiang;ZHAO Guofen(Key Lab of Germplasm Innovation and Utilization of Triticeae Crop at Universities of Inner Mongolia Autonomous Region,College of Life Sciences,Inner Mongolia Agricultural University,Hohhot 010011,China;State Key Laboratory of Pathogen and Biosecurity,Academy of Military Medical Sciences,Academy of Military Sciences,Beijing 100071,China)

机构地区：[1]内蒙古农业大学生命科学学院,麦类种质创新利用自治区高等学校重点实验室,呼和浩特010011 [2]军事科学院军事医学研究院,病原微生物生物安全全国重点实验室,北京100071

出　　处：《军事医学》2024年第11期853-857,共5页Military Medical Sciences

基　　金：国家重点研发计划(2023YFC2308002)。

摘　　要：近年来,由A族链球菌感染引发的突发社会公共卫生事件给社会造成了严重的经济负担。A族链球菌疫苗研发始终是研究人员关注与研究的焦点,目前已有多种类型的疫苗正处于不同的研发阶段,然而仍未有成熟可用的疫苗可供使用。该文从M蛋白重组蛋白疫苗、非M蛋白重组蛋白疫苗以及多糖结合疫苗等方面综述A族链球菌疫苗研究现状。In recent years,sudden public health events caused by group A streptococcus infections have been emerging,imposing a huge economic burden on society.The development of group A streptococcus vaccines has been an area of great interest to scientists.There is currently a wide range of vaccines in different stages of development.However,no mature and usable vaccines are available so far.This paper reviewed the current research on group A streptococcus vaccines in general and on M-protein recombinant protein vaccines,non-M-protein recombinant protein vaccines,and polysaccharide conjugate vaccines in particular.

关 键 词：A族链球菌 重组蛋白疫苗 多糖结合疫苗 

分 类 号：R378.12[医药卫生—病原生物学]